REPRODUCTIVE HEALTH IN TRANS AND GENDER DIVERSE PATIENTS: Effects of feminizing gender-affirming hormone therapy on testicular function and reproductive capacity: review of data from clinical and experimental studies
Reproduction · 2024
DOI: 10.1530/rep-24-0046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reproduction, 2024. Verfasst von Kenny A Rodriguez-Wallberg und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Reproductive Health, Testis. Die Arbeit nennt 84 Literaturangaben.
Abstract (Originalsprache)
In brief Transgender, non-binary and gender-diverse patients utilizing feminizing gender-affirming hormone therapy (GAHT) may experience reduced fertility, which is currently addressed through fertility preservation and treatment cessation. Experimental research with animal models may identify mechanisms involved in testicular function impairment, their severity and duration, and may help to inform patients about reproductive health decisions. Abstract Feminizing GAHT may include combined estrogen, progesterone and/or antiandrogens (collectively referred to as E-GAHT) aiming to achieve individualized embodiment goals. This kind of treatment is highly desired, but it is expected to negatively impact the reproductive ability of transgender, non-binary and/or gender-diverse (TNG) individuals having testes, mainly by disrupting the biological pathways involved in spermatogenesis. There is little research on the impact of E-GAHT on the testis or on the potential recovery of spermatogenesis by stopping GAHT. Studies using animal models receiving GAHT are a novel promising method to help identify the reproductive pathways affected by GAHT and the degree of those effects. A literature search was performed to identify both clinical and experimental studies using rodent models applicable to the reproductive needs of E-GAHT users. We found large variability in clinical populations that has not been fully replicated in translational research. Furthermore, animal GAHT models have yet to be capitalized to examine fertility preservation. Some clinical studies indicated that sperm quality may be reduced in E-GAHT patients before initiating E-GAHT, which cannot be studied using GAHT-treated animals. As many TNG people of reproductive age may have the wish to create a future family, it is important to increase the knowledge that will inform and improve E-GAHT patients’ fertility preservation outcomes and reproductive health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
ORCID-Profile: Kenny A Rodriguez-Wallberg, Daniel R Pfau
Zitieren
APA
Rodriguez-Wallberg, K. A., & Pfau, D. R. (2024). REPRODUCTIVE HEALTH IN TRANS AND GENDER DIVERSE PATIENTS: Effects of feminizing gender-affirming hormone therapy on testicular function and reproductive capacity: review of data from clinical and experimental studies. Reproduction. https://doi.org/10.1530/rep-24-0046
Vancouver
Rodriguez-Wallberg KA, Pfau DR. REPRODUCTIVE HEALTH IN TRANS AND GENDER DIVERSE PATIENTS: Effects of feminizing gender-affirming hormone therapy on testicular function and reproductive capacity: review of data from clinical and experimental studies. Reproduction. 2024. doi:10.1530/rep-24-0046
BibTeX
@article{RodriguezWallberg2024,
author = {Rodriguez-Wallberg, Kenny A and Pfau, Daniel R},
title = {REPRODUCTIVE HEALTH IN TRANS AND GENDER DIVERSE PATIENTS: Effects of feminizing gender-affirming hormone therapy on testicular function and reproductive capacity: review of data from clinical and experimental studies},
journal = {Reproduction},
year = {2024},
doi = {10.1530/rep-24-0046}
}
EUVIMED